Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Significant Decline in Short Interest

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 17,610,000 shares, a decline of 5.3% from the September 30th total of 18,600,000 shares. Based on an average daily volume of 648,300 shares, the days-to-cover ratio is currently 27.2 days.

Karyopharm Therapeutics Trading Up 14.7 %

KPTI traded up $0.12 during trading on Thursday, hitting $0.96. 6,429,623 shares of the company’s stock traded hands, compared to its average volume of 1,265,074. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company’s 50 day simple moving average is $0.80 and its two-hundred day simple moving average is $0.92. The stock has a market capitalization of $120.10 million, a price-to-earnings ratio of -0.76 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.09. The business had revenue of $42.79 million during the quarter, compared to the consensus estimate of $36.07 million. On average, equities analysts expect that Karyopharm Therapeutics will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Karyopharm Therapeutics during the second quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new position in Karyopharm Therapeutics in the second quarter worth approximately $167,000. Exchange Traded Concepts LLC boosted its stake in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares during the last quarter. Finally, Ikarian Capital LLC grew its position in shares of Karyopharm Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after acquiring an additional 9,355 shares during the period. Institutional investors own 66.44% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KPTI shares. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).